((自动化翻译由路透提供，请见免责声明 ))
10月29日 - ** 制药商Incyte 股价上涨约8%至70.95美元，创5月份以来新高
** Incyte预计， (link) 2024年其血癌药物Jakafi的销售额将在27.4亿美元至27.7亿美元之间，而之前的预测为27.1亿美元至27.5亿美元。
** 公司第三季度营收为 11.4 亿美元，高于分析师平均预期的 10.7 亿美元 - LSEG
** Cantor Fitzgerald 的分析师说："我们认为 INCY 的基础业务在 2029 年初之前都是稳定到适度增长的现金奶牛，预计届时 Jakafi 将成为仿制药。
** 包括本交易日的走势在内，该股今年累计上涨 13
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.